title: Neuroscience networking: linking discovery to drugs.
abstract: Discoveries in the pre-clinical neurosciences have set the stage for bringing new therapies to patients affected by neurological disorders. The National lnstitute of Neurological Disorders and Stroke (NINDS) is dedicated to promoting the development of new therapies through its funding programs that range from basic neuroscience to translational research and finally clinical research to test the most promising new therapies in patients. In an effort to accelerate the translation of new discoveries to clinical practice, NINDS is piloting novel organizational strategies. In translational research, NINDS is taking the lead on the establishment of a 'virtual pharma' structure, through which researchers will partner with the NIH to accelerate the progress of drug development from early hit discovery through phase 1 clinical trials. In clinical research, the new Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) aims to promote the efficient implementation of scientifically sound, biomarker-informed phase 2 clinical trials that can be initiated by academic or industry investigators.
authors.affiliation: Office of Translational Research, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA. jill.heemskerk@nih.gov
authors.forename: Jill
authors.initials: J
authors.lastname: Heemskerk
authors.forename: Rebecca
authors.initials: R
authors.lastname: Farkas
authors.forename: Petra
authors.initials: P
authors.lastname: Kaufmann
mesh_terms: D000818:Animals; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D009042:Motivation / Q000502:physiology*; D055825:National Institute of Neurological Disorders and Stroke (U.S.) / Q000639:trends*; D009480:Neuropharmacology / Q000639:trends*; D009488:Neurosciences / Q000639:trends*; D014481:United States